377 A Randomized, Double-Blind, Placebo-Controlled Trial with a Novel Dual Noradrenergic Reuptake Inhibitor (NARI) and 5-HT3 Antagonist: Results of a Phase II 8-Week Study in Female Patients with Diarrhea Predominant Irritable Bowel Syndrome (D-IBS)

2008 ◽  
Vol 134 (4) ◽  
pp. A-50 ◽  
Author(s):  
William G. Paterson ◽  
Jonathon Springer ◽  
Michael O'Mahony ◽  
Richard P. Reynolds ◽  
Subhas C. Ganguli ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Phase Ii ◽  
Reuptake Inhibitor ◽  
Controlled Trial ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Female Patients ◽  
Irritable Bowel

scholarly journals The Effect of Phloroglucinol in Patients With Diarrhea-predominant Irritable Bowel Syndrome: A Randomized, Double-blind, Placebo-controlled Trial

2020 ◽  
Vol 26 (1) ◽  
pp. 117-127 ◽  
Author(s):  
Seung Yong Shin ◽  
Bong Ki Cha ◽  
Won-Seok Kim ◽  
Jae Yong Park ◽  
Jeong Wook Kim ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Controlled Trial ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Irritable Bowel

Effect of multispecies probiotics on irritable bowel syndrome: A randomized, double-blind, placebo-controlled trial

2013 ◽  
Vol 29 (1) ◽  
pp. 52-59 ◽  
Author(s):  
Jun Sik Yoon ◽  
Won Sohn ◽  
Oh Young Lee ◽  
Sang Pyo Lee ◽  
Kang Nyeong Lee ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Controlled Trial ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Irritable Bowel
Sign in / Sign up

Export Citation Format

Share Document